X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs WOCKHARDT LTD. - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA WOCKHARDT LTD. TORRENT PHARMA/
WOCKHARDT LTD.
 
P/E (TTM) x 36.6 -12.8 - View Chart
P/BV x 6.5 1.5 426.5% View Chart
Dividend Yield % 0.8 0.0 31,156.5%  

Financials

 TORRENT PHARMA   WOCKHARDT LTD.
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
WOCKHARDT LTD.
Mar-18
TORRENT PHARMA/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs1,5501,012 153.2%   
Low Rs1,144532 215.1%   
Sales per share (Unadj.) Rs354.7355.9 99.7%  
Earnings per share (Unadj.) Rs40.1-60.3 -66.5%  
Cash flow per share (Unadj.) Rs64.2-46.8 -137.3%  
Dividends per share (Unadj.) Rs14.000.01 140,000.0%  
Dividend yield (eoy) %1.00 80,226.5%  
Book value per share (Unadj.) Rs273.1257.8 105.9%  
Shares outstanding (eoy) m169.22110.63 153.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.82.2 175.1%   
Avg P/E ratio x33.6-12.8 -262.5%  
P/CF ratio (eoy) x21.0-16.5 -127.1%  
Price / Book Value ratio x4.93.0 164.7%  
Dividend payout %34.90 -210,579.3%   
Avg Mkt Cap Rs m227,89785,379 266.9%   
No. of employees `00014.76.3 235.0%   
Total wages/salary Rs m11,3539,371 121.2%   
Avg. sales/employee Rs Th4,083.06,295.0 64.9%   
Avg. wages/employee Rs Th772.31,498.3 51.5%   
Avg. net profit/employee Rs Th461.3-1,066.3 -43.3%   
INCOME DATA
Net Sales Rs m60,02139,369 152.5%  
Other income Rs m2,9881,202 248.6%   
Total revenues Rs m63,00940,571 155.3%   
Gross profit Rs m13,49318 73,729.5%  
Depreciation Rs m4,0861,495 273.3%   
Interest Rs m3,0852,555 120.7%   
Profit before tax Rs m9,310-2,830 -329.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m2,529257 983.9%   
Profit after tax Rs m6,781-6,669 -101.7%  
Gross profit margin %22.50 48,360.9%  
Effective tax rate %27.2-9.1 -299.0%   
Net profit margin %11.3-16.9 -66.7%  
BALANCE SHEET DATA
Current assets Rs m52,62333,796 155.7%   
Current liabilities Rs m52,02226,917 193.3%   
Net working cap to sales %1.017.5 5.7%  
Current ratio x1.01.3 80.6%  
Inventory Days Days12079 150.7%  
Debtors Days Days7689 85.4%  
Net fixed assets Rs m85,01639,664 214.3%   
Share capital Rs m846553 153.0%   
"Free" reserves Rs m45,37627,968 162.2%   
Net worth Rs m46,22228,522 162.1%   
Long term debt Rs m41,11521,731 189.2%   
Total assets Rs m142,43281,620 174.5%  
Interest coverage x4.0-0.1 -3,737.1%   
Debt to equity ratio x0.90.8 116.7%  
Sales to assets ratio x0.40.5 87.4%   
Return on assets %6.9-5.0 -137.4%  
Return on equity %14.7-23.4 -62.8%  
Return on capital %14.2-7.7 -184.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,5809,807 148.7%   
Fx outflow Rs m3,6001,789 201.3%   
Net fx Rs m10,9808,019 136.9%   
CASH FLOW
From Operations Rs m8,942684 1,306.5%  
From Investments Rs m-47,0706,302 -746.9%  
From Financial Activity Rs m34,174-7,695 -444.1%  
Net Cashflow Rs m-3,655-664 550.5%  

Share Holding

Indian Promoters % 71.5 74.5 96.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 2.3 305.2%  
FIIs % 12.6 7.7 163.6%  
ADR/GDR % 0.0 0.1 -  
Free float % 8.8 15.4 57.1%  
Shareholders   26,511 67,757 39.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   CIPLA  PFIZER  ALEMBIC PHARMA  SHASUN PHARMA  SANOFI INDIA  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 404 Points Higher; Metal and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets continued their momentum during closing hours and ended the day on a strong note. Gains were largely seen in the metal sector and oil & gas sector.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (3QFY19); Net Profit Down 80.6% (Quarterly Result Update)

Jan 29, 2019 | Updated on Jan 29, 2019

For the quarter ended December 2018, WOCKHARDT LTD. has posted a net profit of Rs 769 m (down 80.6% YoY). Sales on the other hand came in at Rs 10 bn (up 4.0% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (2QFY19); Net Profit Down 158.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, WOCKHARDT LTD. has posted a net profit of Rs 228 m (down 158.2% YoY). Sales on the other hand came in at Rs 11 bn (up 10.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)

Feb 7, 2019

Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)

Feb 8, 2019

This is the trick to following super investors and not losing money.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Feb 20, 2019 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS